Author's response to reviews

Title: Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases.

Authors:

Holland C Detke (detkehc@lilly.com)
David P McDonnell (mcdonnelldp@lilly.com)
Elizabeth Brunner (ebrunner@lilly.com)
Fangyi Zhao (zhaofa@lilly.com)
Sebastian Sorsaburu (sorsaburu_s@lilly.com)
Victoria J Stefaniak (victoria_jennifer.stefaniak@lilly.com)
Sara A Corya (scorya@lilly.com)

Version: 3 Date: 7 June 2010

Author's response to reviews: see over
7 June 2010

Melissa Norton, MD
Editor-in-Chief, BMC Psychiatry
BioMed Central Ltd, Floor 6
236 Gray's Inn Road
London, WC1X 8HL, United Kingdom

Re: MS# 5816706623192332

Dear Dr. Norton:

Thank you very much for your review of our manuscript, “Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases.” Please find below a point-by-point listing of all the changes that have been made to the last version of the manuscript. Please let us know if there is anything else that we need to provide.

Thanks again for your assistance.

Sincerely,

Holland Detke, PhD
Senior Clinical Research Scientist
Eli Lilly & Company
**Major revisions**

1. Abstract: please ensure that the Abstract is present in manuscript and matches exactly what is in the submission system. At present the trial registration number is not present in the submission system.

   **Response: Done.**

2. Appendix: Your appendix includes tables. Please either include these as additional files or remove the lines and include the information as normal text.

   **Response: We have reformatted Appendix B as normal text now.**

**Minor revisions**

1. Qualifications: Please remove the authors' qualifications (e.g. PhD / MD) or job titles from the manuscript and submissions system

   **Response: Done.**

2. Highlighting/tracking: Please remove all highlighting and tracking from the manuscript.

   **Response: Done.**

3. Underlining: Please note that underlining is not supported in the final full text; you may wish to change it to bold.

   **Response: We have changed all underlining to bold text instead.**

4. Appendix: This should be placed before the Acknowledgements section of the manuscript.

   **Response: Done.**

5. Figures: It is important for the final layout of the manuscript that the figures are cropped as closely as possible to minimise white space around the image.

   **Response: Done.**

6. Typography: Please take this opportunity to check your manuscript for any typographical errors and to make any final corrections or revisions. This is the final proofing stage for your manuscript, and you will not be able to make any changes after acceptance.

   **Response: The following additional corrections have been made to the manuscript and figures:**

   - Changed punctuation in manuscript title to be consistent with AMA style guidelines (10th edition). Main title followed by a comma, then the numeral I, then a colon before the remainder
of the title. The title of the companion manuscript (II) has also been changed accordingly as well as in the reference list of the present paper (reference 5).

- Added mailing address for corresponding author on title page
- On p.5, changed “F.Ovale” to “f. ovale”
- Corrected subtitle on p.6 (“Olanzapine LAI Injection Procedures”) to lower case to be consistent with all other subtitles (“Olanzapine LAI injection procedures”)
- Corrected titles of references 2, 3, 8, 9, 10, and 13
- Updated web address for references 3, 8, 9, and 10 so that it links directly to the article rather than a table of contents page
- Changed reference 5 to 'in press' as manuscript has been accepted for publication
- Corrected date for reference 7
- Noted references 16, 18, and 19 are abstracts
- Corrected a spelling error in reference 12
- Deleted “Last accessed on…” statements from website citations
- On Figure 1, corrected label for middle bar in figure from “<1 to 3” to “1 to 3” and changed x-axis label from “Hours” to “Hours after Injection” for added clarity.
- Reinserted the Additional Material section which was accidentally left off of the previous version submitted
- In correcting the website citations, it was noticed that there was an inaccuracy in the text in the 2nd paragraph on p.4. The statement previously shown as supported by references 6-11 should only be supported by references 6 and 7. References 8 through 11 now support a separate statement added to the last sentence of that paragraph. Also, “phenergan” (a brand name) is now replaced by the generic name “promethazine.” See paragraph with track changes here:

“Accidental intravascular injection is a known risk for all intramuscularly injected products and is typically reflected in label warnings. One product with a well-documented example of a post-injection syndrome following accidental intravascular injection is penicillin procaine G [6,447]. When injected intravascularly, the salt formulation dissociates into its penicillin and procaine components, resulting in procaine toxicity, which produces a clear symptomatic presentation known as Hoigne’s syndrome. Other intramuscularly injected products that can result in noticeable symptoms following accidental intravascular injection include other long-acting penicillins [8-11], various anesthetic agents used during dental procedures (e.g., Septocaine [12]), as well as phenergan-promethazine [13], barbiturates and benzodiazepines [14].”